AU2021201208A1 — Assays for diagnosing and evaluating treatment options for fabry disease
Assigned to Amicus Therapeutics Inc · Expires 2021-03-25 · 5y expired
What this patent protects
Provided is a method for the treatment of Fabry disease in a human patient with a specific a-galactosidase A mutation comprising administering to the patient an effective amount of 1-deoxygalactonojirimycin. Figure 3 0 Z 120 a 100 ~60. ~40 E520 C NL R3IQ A97V R356W 6132R A…
USPTO Abstract
Provided is a method for the treatment of Fabry disease in a human patient with a specific a-galactosidase A mutation comprising administering to the patient an effective amount of 1-deoxygalactonojirimycin. Figure 3 0 Z 120 a 100 ~60. ~40 E520 C NL R3IQ A97V R356W 6132R AM4P A97V A143P W Fib Fib a -Gal~ 0o 5/7
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.